Akhbari Masoume, Khalili Mitra, Shahrabi-Farahani Maryam, Biglari Alireza, Bandarian Fatemeh
Clin Lab. 2019 Aug 1;65(8). doi: 10.7754/Clin.Lab.2019.190209.
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Several factors are known to contribute to the development and progression of diabetic nephropathy. Different microRNAs have been shown to contribute in the pathogenesis of DN. This study, aimed to evaluate the expression level of circulating miR-155 in patients with diabetic nephropathy.
In this case-control study, 83 diabetic patients and normal subjects were evaluated in four groups of normal healthy subjects without diabetes and nephropathy, diabetes without nephropathy, diabetes with microalbuminuria, and diabetes with macroalbuminuria. After RNA extraction from serum and cDNA synthesis, the expression of circulating miR-155 was evaluated by quantitative polymerase chain reaction (qPCR).
Expression level of cell-free miR-155 was significantly lower in diabetics compared to the normal healthy controls (p < 0.05). However, no significant difference was found in miR-155 expression level between different diabetes groups with different conditions of kidney function. Furthermore, we detected a significant negative correlation between cell-free miR-155 expression and GFR only in patients with microalbuminuria (r = -0.70, p = 0.001).
It seems that miR-155 can discriminate diabetic and nondiabetic status, but is not an appropriate biomarker for tracking of macroalbuminuria.
糖尿病肾病（DN）是全球终末期肾病的主要原因。已知有几个因素会导致糖尿病肾病的发生和发展。不同的微小RNA已被证明在糖尿病肾病的发病机制中起作用。本研究旨在评估糖尿病肾病患者循环miR-155的表达水平。
在这项病例对照研究中，83名糖尿病患者和正常受试者被分为四组：无糖尿病和肾病的正常健康受试者、无肾病的糖尿病患者、微量白蛋白尿的糖尿病患者和大量白蛋白尿的糖尿病患者。从血清中提取RNA并合成cDNA后，通过定量聚合酶链反应（qPCR）评估循环miR-155的表达。
与正常健康对照组相比，糖尿病患者中游离miR-155的表达水平显著降低（p < 0.05）。然而，在不同肾功能状况的不同糖尿病组之间，miR-155表达水平未发现显著差异。此外，仅在微量白蛋白尿患者中，我们检测到游离miR-155表达与肾小球滤过率（GFR）之间存在显著负相关（r = -0.70，p = 0.001）。
似乎miR-155可以区分糖尿病和非糖尿病状态，但不是追踪大量白蛋白尿的合适生物标志物。
